Comparison of droperidol and ondansetron prophylactic effect on subarachnoid morphine-induced pruritus

Fabio Ferreira da Cunha Briãoa,*, Marcio Leal Hortaa, Bernardo Lessa Hortaab, Guilherme Antônio Moreira de Barrosc, Ana Paula Behrensdorf, Ingrid Severod, Mariana Antunes Nuned, Roberta Boabaid, André Real
d

Abstract
Background and objectives: The prophylactic effect of ondansetron on subarachnoid morphine-induced pruritus is controversial, while evidence suggests that droperidol prevents pruritus. The aim of this study is to compare the effects of droperidol and ondansetron on subarachnoid morphine-induced pruritus.

Methods: 180 ASA I or II patients scheduled to undergo cesarean sections under subarachnoid anesthesia combined with morphine 0.2 mg were randomized to receive, after the child’s birth, metoclopramide 10 mg (Group I – control), droperidol 2.5 mg (Group II) or ondansetron 8 mg (Group III). Postoperatively, the patients were assessed for pruritus (absent, mild, moderate or severe) or other side effects by blinded investigators. Patients were also blinded to their group allocation. The tendency to present more severe forms of pruritus was compared between groups. NNT was also determined.

Results: Patients assigned to receive droperidol [Proportional odds ratio: 0.45 (95% confidence interval 0.23–0.88)] reported less pruritus than those who received metoclopramide. Ondansetron effect was similar to metoclopramide [Proportional odds ratio: 0.95 (95% confidence interval 0.49–1.83)]. The NNT for droperidol and ondansetron was 4.0 and 14.7, respectively.

Conclusions: Ondansetron does not inhibit subarachnoid morphine-induced pruritus.

© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.

Keywords
Droperidol;
Morphine;
Ondansetron;
Pruritus;
Subarachnoid injection
Introduction

In a previous work, we compare the prophylactic effect of droperidol, alizapride, propofol, and promethazine on subarachnoid morphine-induced pruritus. Droperidol was the most effective agent; propofol and alizapride were less efficient; and promethazine, as other antihistamines, was ineffective. Kjebib and Tramér, in a review study of pharmacological treatment of morphine-induced pruritus, concluded that droperidol was more effective than any other drug, other than morphine antagonists. But their review only included one study in which ondansetron was used to antagonize the alfentanil-induced pruritus in patients undergoing general surgery.

Evidences of ondansetron effectiveness are contradictory. Some studies have reported ondansetron effectiveness for treating or preventing pruritus. It has also been suggested that ondansetron reduces pruritus severity without reducing its incidence. On the other hand, other studies have reported the ineffectiveness of ondansetron or its lower efficacy compared to other drugs.

Given this contradiction and lack of comparison between droperidol and ondansetron, we decided to compare the prophylactic effect of the two drugs in patients undergoing cesarean section (C-section).

Methods

This study was approved by the Research Ethics Committee of the Universidade Católica de Pelotas (Ref: 2011/18), and written informed consent was obtained from all patients.
with fractionated doses of metaraminol. Shortly after birth, 15–20 units of oxytocin were used to obtain good uterine contraction. In three cases, 0.2 mg of methylergometrine were used for the same purpose.

The distribution of 180 participants in three groups of 60 patients was performed using a table of random numbers. According to this allocation table, immediately after birth, the patients in Group I received metoclopramide (10 mg); patients in Group II received droperidol (2.5 mg); and patients in Group III received ondansetron (8 mg) (Fig. 1). In Group I, metoclopramide was used because it was shown that it has no effect on morphine-induced pruritus, so it can be used to prevent nausea and vomiting and as a placebo for morphine-induced pruritus. Induction of anesthesia and administration of drugs in the operating room were performed by anesthesiologists (FFCB and MLH). In the postoperative period, patients were seen by anesthesiologists unaware to their experimental allocation (APB, IS, MAN, RB, and RA). The patients were also blinded to the treatment received, characterizing the double-blind nature of this study. Patients were evaluated every six hours for a period of 24 h. After this period, they were evaluated twice daily until discharge from hospital. In addition to pruritus, any other adverse effects seen or reported by the patient, even if only in one of the visits, was recorded and considered positive.

Pruritus was classified as absent; mild (restricted to one area, such as face or arms, and not disturbing the patient, sometimes denied and only reported after insistence); moderate (affecting a larger area, such as face and arms or face and anterior surface of the chest, but not disturbing the patient and therefore not requiring treatment) or intensive (extensive or generalized pruritus, often disturbing

the patient to the point where treatment is indicated). It was registered according to the highest intensity seen or reported. If treatment was necessary, droperidol 1.25 mg was used intravenously.

Based on previous studies, we estimate that the incidence of moderate or severe pruritus should be 30% in the control group, and that an effective intervention would reduce the incidence by 60%. The sample size calculation estimated 60 patients per group for a significance level of 95% and a power of 80%.

For data analysis, we used logistic regression to estimate the trend of moderate or severe pruritus and the proportional trend model to estimate the tendency to present a more severe pruritus. In ordinal regression, the proportional model was used to estimate the odds ratio and the presumption of proportional odds was assessed using Brant test. NNT evaluation was based on the incidence of moderate or severe pruritus.

Results

Table 1 shows that the distribution of some basic characteristics (age, weight, height, BMI, fasting time, number of previous C-sections, and incidence of postoperative nausea or vomiting) was similar between groups. There was no difference between groups in fluid replacement volume or proportion of patients who received treatment for hypotension.

Table 2 shows that the proportion of subjects who reported the occurrence of pruritus or the occurrence of mild pruritus was higher among patients in droperidol group.
Table 1  Distribution of the basic characteristics of the three groups.

<table>
<thead>
<tr>
<th></th>
<th>Metoclopramide</th>
<th>Droperidol</th>
<th>Ondansetron</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>27.1</td>
<td>27.6</td>
<td>26.8</td>
<td>0.82</td>
</tr>
<tr>
<td>ASA I patients (%)</td>
<td>55.0</td>
<td>58.3</td>
<td>63.3</td>
<td>0.65</td>
</tr>
<tr>
<td>Weight</td>
<td>81.5</td>
<td>84.7</td>
<td>78.7</td>
<td>0.20</td>
</tr>
<tr>
<td>Height</td>
<td>162.1</td>
<td>163.1</td>
<td>162.0</td>
<td>0.78</td>
</tr>
<tr>
<td>Body mass index</td>
<td>30.8</td>
<td>31.8</td>
<td>29.4</td>
<td>0.18</td>
</tr>
<tr>
<td>Fasting time</td>
<td>8.12</td>
<td>8.84</td>
<td>8.18</td>
<td>0.41</td>
</tr>
<tr>
<td>Previous cesarean</td>
<td>26.7</td>
<td>35.6</td>
<td>45.0</td>
<td>0.11</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>3.3</td>
<td>5.0</td>
<td>6.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Volume up to anesthesia</td>
<td>146.8</td>
<td>143.1</td>
<td>163.0</td>
<td>0.74</td>
</tr>
<tr>
<td>Volume up to birth</td>
<td>245.7</td>
<td>254.6</td>
<td>308.7</td>
<td>0.23</td>
</tr>
<tr>
<td>Final volume</td>
<td>504.2</td>
<td>538.8</td>
<td>369.1</td>
<td>0.67</td>
</tr>
<tr>
<td>Hypotension (%)</td>
<td>40.0</td>
<td>35.0</td>
<td>48.3</td>
<td>0.16</td>
</tr>
</tbody>
</table>

Table 2  Incidence and severity of pruritus in the three groups.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Absent</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide</td>
<td>9 (15%)</td>
<td>19 (31.7%)</td>
<td>25 (41.7%)</td>
<td>7 (11.7%)</td>
</tr>
<tr>
<td>Droperidol</td>
<td>14 (23.3%)</td>
<td>29 (48.3%)</td>
<td>12 (20%)</td>
<td>5 (8.3%)</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>9 (15%)</td>
<td>23 (38.3%)</td>
<td>17 (28.3%)</td>
<td>11 (18.3%)</td>
</tr>
</tbody>
</table>

Moreover, the incidence of severe pruritus was lower in women assigned to receive droperidol.

Table 3 shows that the tendency to present with a stronger form of pruritus was lower among patients assigned to receive droperidol. The tendency to present with a stronger form of pruritus was 0.45 (95% CI: 0.23–0.88) for patients receiving droperidol compared with those in the metoclopramide group. However, ondansetron group was similar to metoclopramide group. In another approach, we also evaluated the tendency to present with moderate or severe pruritus, using logistic regression. The results of this analysis were similar to those observed in ordinal regression, with patients assigned to receive droperidol presenting less tendency to have moderate or severe pruritus [odds ratio 0.35 (95% CI, 0.16–0.74)].

The NNT for droperidol was 4.0, while that for ondansetron was 14.7.

Discussion

Our results show that droperidol was more effective than metoclopramide and ondansetron both when we approached the trend toward moderate or severe pruritus or when the severity of pruritus was the approach point.

There are some possible explanations for the differences in our results and those reported in the literature. First, opioids are different in their pharmacokinetics, and morphine has a very long action when administered by the subarachnoid route. Therefore, it is very difficult to compare fentanyl or sufentanil with morphine. Another difference is that the incidence of pruritus in C-section is higher than in other surgeries.

Regarding the safety of the use of droperidol, there are reports of arrhythmias, but it was not seen in our previous investigation, when we use 1.25 mg of droperidol in 60 patients, neither in this study with the dose of 2.5 mg. In any case, it seems interesting to use lower doses of droperidol in order to study its effectiveness.

In summary, our study shows that ondansetron does not inhibit subarachnoid morphine-induced pruritus in patients undergoing C-section. These results, combined with our previous results, allow us to say that droperidol is a satisfactory drug to antagonize the subarachnoid morphine-induced pruritus.

Table 3  Ordinal and logistic regression of groups 2 and 3 (droperidol and ondansetron, respectively), having group 1 (metoclopramide) as a reference.

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinal regression – odds ratio (95% confidence interval)</td>
<td>Reference</td>
<td>0.45 (0.24–0.88)</td>
<td>0.95 (0.49–1.83)</td>
</tr>
<tr>
<td>Logistic regression – odds ratio of persisting moderate to severe pruritus (95% confidence interval)</td>
<td>Reference</td>
<td>0.35 (0.16–0.74)</td>
<td>0.77 (0.37–1.57)</td>
</tr>
</tbody>
</table>
Conflicts of interest

The authors declare no conflicts of interest.

References